The right tools at the right time

Chest

Volumn 130, Issue 1 SUPPL., 2006, Pages 29S-40S

  Humbert, Marc ^a  

^a HÔPITAL ANTOINE BÉCLÈRE   (France)

Author keywords

Add on therapy; Asthma; Early intervention; Inhaled corticosteroids; Management guidelines

Indexed keywords

ACETYLSALICYLIC ACID; ALLERGEN; BECLOMETASONE DIPROPIONATE; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BUDESONIDE; CORTICOSTEROID; FLUTICASONE PROPIONATE; IMMUNOGLOBULIN E; LEUKOTRIENE RECEPTOR BLOCKING AGENT; MONTELUKAST; OMALIZUMAB; PLACEBO; SALBUTAMOL; THEOPHYLLINE; ZAFIRLUKAST; ZILEUTON;

ABSENTEEISM; ADD ON THERAPY; ADULT; ASTHMA; CARDIOVASCULAR DISEASE; CHILD; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL PRACTICE; CONFERENCE PAPER; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DISEASE EXACERBATION; DISEASE SEVERITY; EARLY DIAGNOSIS; EXERCISE INDUCED ASTHMA; FORCED EXPIRATORY VOLUME; HEART ARREST; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HEART VENTRICLE TACHYCARDIA; HOSPITAL ADMISSION; HUMAN; IMMUNOTHERAPY; LUNG FUNCTION TEST; MAJOR CLINICAL STUDY; MONOTHERAPY; PRACTICE GUIDELINE; PRIORITY JOURNAL; RISK FACTOR; SIDE EFFECT; SINUS TACHYCARDIA; SUDDEN DEATH; SYMPTOMATOLOGY; SYNCOPE;

EID: 33746299298     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.130.1_suppl.29S     Document Type: Conference Paper

References (50)

1. Masoli M, Fabian D, Holt S, et al. Global Initiative for Asthma (GINA) program: the global burden of asthma; executive summary of the GINA Dissemination Committee report. Allergy 2004; 59:469-478
2. National Asthma Education and Prevention Program. Expert panel report 2: guidelines for the diagnosis and management of asthma. Bethesda, MD: National Institutes of Health, 1997; publication No. 97-4051
3. Global Initiative for Asthma. GINA workshop report: global strategy for asthma management and prevention. Available at: www.ginasthma.com/. Accessed June 20, 2006
4. van Schayck CP, van Der Heijden FM, van Den Boom G, et al. Underdiagnosis of asthma: is the doctor or the patient to blame? The DIMCA project. Thorax 2000; 55:562-565
5. Braman SS. Asthma in the elderly. Clin Geriatr Med 2003; 19:57-75
6. Speight AN, Lee DA, Hey EN. Underdiagnosis and undertreatment of asthma in childhood. BMJ (Clin Res Ed) 1983; 286:1253-1256
7. Kaur B, Anderson HR, Austin J, et al. Prevalence of asthma symptoms, diagnosis, and treatment in 12-14 year old children across Great Britain (international study of asthma and allergies in childhood, ISAAC UK). BMJ 1998; 316:118-124
8. Agertoft L, Pedersen S. Effects of long-term treatment with an inhaled corticosteroid on growth and pulmonary function in asthmatic children. Respir Med 1994; 88:373-381
9. Liu AH. Consider the child: how early should we treat? J Allergy Clin Immunol 2004; 113(1 suppl):S19-S24
10. van Weel C. Underdiagnosis of asthma and COPD: is the general practitioner to blame? Monaldi Arch Chest Dis 2002; 57:65-68
11. Irwin RS, Curley FJ, French CL. Chronic cough: the spectrum and frequency of causes, key components of the diagnostic evaluation, and outcome of specific therapy. Am Rev Respir Dis 1990; 141,640-647
12. Montnemery P, Hansson L, Lanke J, et al. Accuracy of a first diagnosis of asthma in primary health care. Fam Pract 2002; 19:365-368
13. Barnes PJ. Asthma guidelines: recommendations versus reality. Respir Med 2004; 98(suppl A):S1-S7
14. Asthma Insights and Reality in Europe. The Asthma Insights and Reality in Europe (AIRE) Study. Available at: www.asthma.ac.psiweb.com/. Accessed June 20, 2006
15. Asthma in America: a landmark survey. GlaxoSmithKline, 1998. Available at: www.asthmainamerica.com; accessed June 20, 2006
16. Rabe KF, Vermeire PA, Soriano JB, et al. Clinical management of asthma in 1999: the Asthma Insights and Reality in Europe (AIRE) study. Eur Respir J 2000; 16:802-807
17. Barnes PJ, Pedersen S, Busse WW. Efficacy and safety of inhaled corticosteroids: new developments. Am J Respir Crit Care Med 1998; 157:S1-S53
18. Zeiger RS, Dawson C, Weiss S. Relationships between duration of asthma and asthma severity among children in the Childhood Asthma Management Program (CAMP). J Allergy Clin Immunol 1999; 103:376-387
19. Kupczyk M, Kuprys I, Gorski P, et al. Long-term deterioration of lung function in asthmatic outpatients. Respiration 2004; 71:233-240
20. Haahtela T, Jarvinen M, Kava T, et al. Effects of reducing or discontinuing inhaled budesonide in patients with mild asthma. N Engl J Med 1994; 331:700-705
21. Masoli M, Holt S, Weatherall M, et al. Dose-response relationship of inhaled budesonide in adult asthma: a meta-analysis. Eur Respir J 2004; 23:552-558
22. Pedersen S, O'Byrne P. A comparison of the efficacy and safety of inhaled corticosteroids in asthma. Allergy 1997; 52(suppl):1-34
23. Mash B, Bheekie A, Jones PW. Inhaled vs oral steroids for adults with chronic asthma. Cochrane Database Syst Rev 2001; 1:CD002160
24. The Childhood Asthma Management Program Research Group. Long-term effects of budesonide or nedocromil in children with asthma. N Engl J Med 2000; 343:1054-1063
25. Djukanovic R, Wilson JW, Britten KM, et al. Effect of an inhaled corticosteroid on airway inflammation and symptoms in asthma. Am Rev Respir Dis 1992; 145:669-674
26. 2-agonist, terbutaline, with an inhaled corticosteroid, budesonide, in newly detected asthma. N Engl J Med 1991; 325:388-392
27. Suissa S, Ernst P, Benayoun S, et al. Low-dose inhaled corticosteroids and the prevention of death from asthma. N Engl J Med 2000; 343:332-336
28. 2-adrenoceptor agonism. Br J Clin Pharmacol 2002; 54:231-245
29. Woolcock A, Lundback B, Ringdal N, et al. Comparison of addition of salmeterol to inhaled steroids with doubling of the dose of inhaled steroids. Am J Respir Crit Care Med 1996; 153:1481-1488
30. Bateman ED, Boushey HA, Bousquet J, et al. Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma Control Study. Am J Respir Crit Care Med 2004; 170:836-844
31. Salpeter SR, Ormiston TM, Salpeter EE. Cardiovascular effects of beta-agonists in patients with asthma and COPD: a meta-analysis. Chest 2004; 125:2309-2321
32. Mcivor RA, Pizzichini E, Turner MO, et al. Potential masking effects of salmeterol on airway inflammation in asthma. Am J Respir Crit Care Med 1998; 158:924-930
33. Shapiro G, Lumry W, Wolfe J, et al. Combined salmeterol 50 μg and fluticasone propionate 250 μg in the diskus device for the treatment of asthma. Am J Respir Crit Care Med 2000; 161:527-534
34. Kavuru M, Melamed J, Gross G, et al. Salmeterol and fluticasone propionate combined in a new powder inhalation device for the treatment of asthma: a randomized, double-blind, placebo-controlled trial. J Allergy Clin Immunol 2000; 105:1108-1116
35. Barnes NC. Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma Control study. Am J Respir Crit Care Med 2004; 170:830-831
36. 2-agonists and corticosteroids. Eur Respir J 2002; 19:182-191
37. Laviolette M, Malmstrom K, Lu S, et al. Montelukast added to inhaled beclomethasone in treatment of asthma: Monte-lukast/Beclomethasone Additivity Group. Am J Respir Crit Care Med 1999; 160:1862-1868
38. Virchow CJ, Prasse A, Naya I, et al. Zafirlukast improves asthma control in patients receiving high-dose inhaled corticosteroids. Am J Respir Crit Care Med 2000; 162:578-585
39. Lofdahl CG, Reiss TF, Leff JA, et al. Randomised, placebo controlled trial of effect of a leukotriene receptor antagonist, montelukast, on tapering inhaled corticosteroids in asthmatic patients. BMJ 1999; 319:87-90
40. Ducharme F, Schwartz Z, Hicks G, et al Addition of antileukotriene agents to inhaled corticosteroids for chronic asthma. Cochrane Database Syst Rev 2004; 2:CD003133
41. Busse W, Nelson H, Wolfe J, et al. Comparison of inhaled salmeterol and oral zafirlukast in patients with asthma. J Allergy Clin Immunol 1999; 103:1075-1080
42. Kemp JP. Recent advances in the management of asthma using leukotriene modifiers. Am J Respir Med 2003; 2:139-156
43. Busse W, Corren J, Lanier BQ, et al. Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. J Allergy Clin Immunol 2001; 108:184-190
44. Soler M, Matz J, Townley R, et al. The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics. Eur Respir J 2001; 18:739-740
45. Walker S, Monteil M, Phelan K, et al. Anti-IgE for chronic asthma in adults and children. Cochrane Database Syst Rev 2004; CD003559
46. Ruffin CG, Busch BE. Omalizumab: a recombinant humanized anti-IgE antibody for allergic asthma. Am J Health Syst Pharm 2004; 61:1449-1459
47. Holgate ST, Djukanovic R, Casale T, et al. Anti-immunoglobulin E treatment with omalizumab in allergic diseases: an update on anti-inflammatory activity and clinical efficacy. Clin Exp Allergy 2005; 35:408-416
48. Abramson MJ, Puy RM, Weiner JM. Allergen immunotherapy for asthma. Cochrane Database Syst Rev 2003; CD001186
49. Taylor DM, Auble TE, Calhoun WJ, et al. Current outpatient management of asthma shows poor compliance with international consensus guidelines. Chest 1999; 116:1638-1645
50. Christakis DA, Mell L, Koepsell TD, et al. Association of lower continuity of care with greater risk of emergency department use and hospitalization in children. Pediatrics 2001; 107:524-529